Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Deferred Tax Liability: 2016-2019

  • Niagen Bioscience's Non-Current Deferred Tax Liability rose 59.12% to $218,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $218,000, marking a year-over-year increase of 59.12%. This contributed to the annual value of $218,000 for FY2019, which is 59.12% up from last year.
  • Latest data reveals that Niagen Bioscience reported Non-Current Deferred Tax Liability of $218,000 as of Q4 2019, which was up 59.12% from $137,000 recorded in Q4 2018.
  • Over the past 5 years, Niagen Bioscience's Non-Current Deferred Tax Liability peaked at $413,000 during Q1 2016, and registered a low of $137,000 during Q4 2018.
  • Its 3-year average for Non-Current Deferred Tax Liability is $166,333, with a median of $144,000 in 2017.
  • Per our database at Business Quant, Niagen Bioscience's Non-Current Deferred Tax Liability crashed by 63.91% in 2017 and then soared by 59.12% in 2019.
  • Over the past 4 years, Niagen Bioscience's Non-Current Deferred Tax Liability (Quarterly) stood at $399,000 in 2016, then crashed by 63.91% to $144,000 in 2017, then fell by 4.86% to $137,000 in 2018, then surged by 59.12% to $218,000 in 2019.
  • Its Non-Current Deferred Tax Liability was $218,000 in Q4 2019, compared to $137,000 in Q4 2018 and $144,000 in Q4 2017.